Valeant

B + L places focus on innovation in pharma, surgical, vision careBausch + Lomb (B + L) is more than one of the oldest eye care companies in the industry. It is also one of the broadest, with portfolios in contact lenses, consumer eye products, cataract surgery, intraocular lenses, retina surgery, and a wide range of ophthalmic pharmaceutical products.
Hearing ups pressure on drugmakers’ pricesWhen the House Committee on Oversight and Government Reform met on January 26, legislators took a closer look at price hikes from companies such as Valeant Pharmaceuticals and Turing Pharmaceuticals.
Valeant business practices embroiled in controversyValeant may have hooked up with Walgreen, but it still has a lot to answer for.
Contact lens laboratory files suit against ValeantIn a recent filing, Dallas-based gas permeable (GP) contact lens laboratory TruForm Optics has taken legal action against Valeant Pharmaceuticals. The class-action complaint aims to stop competitive behavior, obtain damages for past competitive behavior, and to restore competitive market conditions.
Valeant responds to drug price concerns with cutsValeant Pharmaceuticals just entered into a new fulfillment agreement with Walgreens and says it will reduce prices of its branded prescription-based dermatological and ophthalmological products such as Jublia by 10 percent.
New psoriasis therapies must demonstrate valuePsoriasis affects a small percentage of the population but price increases for drug treatments have outpaced the Consumer Price Index.
Valeant shakes up GP lens market
Valeant shakes up GP lens marketValeant Pharmaceuticals and its subsidiary Bausch + Lomb have come under fire for its recent actions in purchasing competing gas permeable (GP) contact lens manufacturer Paragon Vision Sciences, attempts to purchase independent GP laboratories, price increases, and withdrawal from industry support group Contact Lens Manufacturers Association (CLMA).
Specialty pharmacy to close over Valeant pricing flapAfter Valeant and Express Scripts cut ties with mail order specialty pharmacy Philidor Rx Services, the company said it would be closing.
New glaucoma drugs aim to shake up marketReuters recently reported on a new wave of drugs in development that it says will shake up glaucoma treatments. When the consumer media is giving your patients direct information about eye care, are you ready to answer their questions?
Acquisition breathes new life into Allergan’s R&D effortsThe recently announced acquisition of Allergan Inc. by Actavis means the Irvine, Calif.-based maker of Botox will no longer be the target of a hostile takeover by Canadian firm Valeant Pharmaceuticals—which in turn means Allergan’s research-and-development programs will continue unabated.